Idera regains IMO-2055 rights from Merck KGaA
Idera entered licensing and collaboration deal with Merck KGaA in December 2007 for the research, development and commercialization of Idera’s TLR9 agonists, including IMO-2055, for the treatment of
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
Under the terms of the deal, Cognizant will offer centralized statistical programming, statistical analysis, medical writing, and document publishing services, covering clinical data reporting, from case report forms